A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck & Co., Inc.) in Healthy Females 18-26 Years of Age
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent Xiamen Innovax Biotech (Primary) ; V 503
- Indications Cervical cancer; Condylomata acuminata
- Focus Pharmacodynamics
- 14 Jun 2023 Status changed from active, no longer recruiting to completed.
- 10 Feb 2022 Planned End Date changed from 1 Dec 2021 to 30 Dec 2022.
- 10 Feb 2022 Planned primary completion date changed from 1 Nov 2021 to 30 Dec 2022.